Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

PURPOSE: In patients with hemophilia B, treatment with extended half-life (EHL) recombinant factor IX allows for longer dosing intervals while providing equal or superior bleeding protection compared with standard half-life products. This enables flexible, individualized treatment schedules, which r...

Descripción completa

Detalles Bibliográficos
Autores principales: Astermark, Jan, Wojciechowski, Piotr, Aballéa, Samuel, Hakimi, Zalmai, Nazir, Jameel, Klamroth, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286734/
https://www.ncbi.nlm.nih.gov/pubmed/34285621
http://dx.doi.org/10.2147/JBM.S312885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286734/
https://www.ncbi.nlm.nih.gov/pubmed/34285621
http://dx.doi.org/10.2147/JBM.S312885

Ejemplares similares